July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Photodynamic therapy for central serous chorioretinopathy with choroidal neovascularization on optical coherence tomography angiography combined with intravitreal anti-vascular endothelial growth factor therapy or alone
Author Affiliations & Notes
  • Nao Sonoda
    Hyogo College of Medicine, Nishinomiya, Hyogo prefecture, Japan
  • Takashi Araki
    Hyogo College of Medicine, Nishinomiya, Hyogo prefecture, Japan
  • Yuki Komuku
    Hyogo College of Medicine, Nishinomiya, Hyogo prefecture, Japan
  • Hisashi Iwami
    Hyogo College of Medicine, Nishinomiya, Hyogo prefecture, Japan
    Iwami Eye Clinic, Japan
  • Fumi Gomi
    Hyogo College of Medicine, Nishinomiya, Hyogo prefecture, Japan
  • Footnotes
    Commercial Relationships   Nao Sonoda, None; Takashi Araki, None; Yuki Komuku, None; Hisashi Iwami, None; Fumi Gomi, Alcon pharma (R), BAYER (R)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 5004. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nao Sonoda, Takashi Araki, Yuki Komuku, Hisashi Iwami, Fumi Gomi; Photodynamic therapy for central serous chorioretinopathy with choroidal neovascularization on optical coherence tomography angiography combined with intravitreal anti-vascular endothelial growth factor therapy or alone. Invest. Ophthalmol. Vis. Sci. 2019;60(9):5004.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the efficacy of photodynamic therapy (PDT) combined with intravitreal anti-vascular endothelial growth factor (VEGF) therapy or alone for central serous chorioretinopathy (CSC) with choroidal neovascularization (CNV) by optical coherence tomography angiography (OCTA).

Methods : A total of 27 eyes of 27 patients (18 men / 9 women, mean age 63.3 ± 10.3 years) with CSC and CNV, treated and followed for 3 months or more between June 2016 and May 2018 at Hyogo College of Medicine were examined. Patients with CSC were identified by fluorescein and indocyanine green angiography, and network structure in the outer retina and choriocapillaris was determined by OCTA. Sixteen (16) patients underwent PDT alone (the PDT group) and 11 underwent PDT combined with intravitreal anti-VEGF therapy within 3 days beforehand (the combination group). We analyzed best corrected visual acuity (BCVA), changes in subretinal fluid, central retinal thickness, subfoveal choroidal thickness, and CNV area before PDT and 1, 3, and 6 months after treatment for each single-treatment group and the combination group.

Results : For the PDT group, logMAR BCVA did not change significantly after treatment. In the combination group, logMAR BCVA improved significantly at 3 and 6 months from baseline (p = 0.043 and p = 0.012). Subretinal fluid was resolved in 62.5% of the cases at 1 month after treatment, 75.0% at 3 months, and 58.3% at 6 months for the PDT group. For the combination group, the rate was 72.7% at 1 month, 72.7% at 3 months, and 66.7% at 6 months. Mean central retinal thickness was significantly reduced at 1, 3 and 6 months for the PDT group and for the combination group. Subfoveal choroidal thickness was significantly reduced at 3 and 6 months for the PDT group (p = 0.0002 and p = 0.021), and at 1, 3 and 6 months for the combination group (p = 0.001, p = 0.001,and p = 0.008). The total CNV area did not significantly change in the PDT group. In the combination group, it was significantly decreased at 1 and 3 months (p = 0.023 and p = 0.037).

Conclusions : PDT combined with anti-VEGF therapy or alone for CSC with CNV significantly improved central retinal thickness and subretinal fluid amounts, but anti-VEGF therapy is necessary to decrease the CNV area.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×